Trial
NCT05494619
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
Chugai Pharmaceutical Co., Ltd. (Sponsor in Taiwan and Japan)
Condition
Guillain-Barré Syndrome
Intervention
Crovalimab
Why stopped
This study has been withdrawn due to an internal decision. The decision was not due to any safety concerns with study drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-15